N@N

Gavin Clark-Gartner Maintained (ABBV) at Buy with Increased Target to $165 on, Feb 9th, 2023

Gavin Clark-Gartner of Evercore ISI Group, Maintained "AbbVie Inc." (ABBV) at Buy with Increased Target from $159 to $165 on, Feb 9th, 2023.

Gavin has made no other calls on ABBV in the last 4 months.

There are 10 other peers that have a rating on ABBV. Out of the 10 peers that are also analyzing ABBV, 6 agree with Gavin's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Navin Jacob of "UBS" Maintained at Hold with Increased Target to $150 on, Tuesday, January 31st, 2023
• Geoff Meacham of "B of A Securities" Maintained at Hold with Increased Target to $165 on, Wednesday, December 14th, 2022
• Navaan Ty of "Exane BNP Paribas" Initiated at Hold and Held Target at $169 on, Thursday, December 8th, 2022
• Justin Smith of "Societe Generale" Downgraded from Strong Buy to Hold on, Tuesday, November 8th, 2022
• Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $155 on, Monday, October 31st, 2022
• Steve Chesney of "Atlantic Equities" Maintained at Hold with Decreased Target to $157 on, Monday, October 31st, 2022

These are the ratings of the 4 analyists that currently disagree with Gavin

---

• Gary Nachman of "BMO Capital" Maintained at Buy with Decreased Target to $167 on, Monday, February 6th, 2023
• Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $157 on, Tuesday, January 17th, 2023
• Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $182 on, Tuesday, December 6th, 2022
• Trung Huynh of "Credit Suisse" Initiated at Buy and Held Target at $170 on, Friday, November 18th, 2022

Contributing Sources

---